2024. Pityriasis Rubra Pilaris, Refractory to IL-17A Inhibition, with Rapid Improvement Following IL-17A/IL-17F Blockade by Bimekizumab. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), 1987–1992. DOI:https://doi.org/10.25251/skin.8.6.13.